Gastro-retentive controlled release tablets of chlordiazepoxide.

Glossary definitions and references:

Scientific and Ayurvedic Glossary list for “Gastro-retentive controlled release tablets of chlordiazepoxide.”. This list explains important keywords that occur in this article and links it to the glossary for a better understanding of that concept in the context of Ayurveda and other topics.

1) Drug:
Chemicals used to diagnose, cure, or prevent diseases. The study centers on Chlordiazepoxide, a drug used for anxiety, examining how modified release formulations can optimize therapeutic effects, reduce side effects, and improve overall treatment compliance and health outcomes for patients taking these medications.

2) Swelling:
The increase in volume of a substance due to the absorption of a liquid. In gastro retentive drug delivery systems, the swelling properties of polymers like HPMC K4M and Xanthum gum are crucial for maintaining tablet integrity and controlling the release rate of the active drug over an extended period.

3) Powder:
A finely ground substance, often used in pharmaceutical formulations for easy dosing and absorption. The powdered form of Chlordiazepoxide and other excipients are crucial in the wet granulation process to ensure homogeneous mixing and consistent drug release profiles in the developed gastro retentive tablets.

4) Maheshwar:
The author of the study, M. Maheshwar, who conducted the research on the formulation and evaluation of controlled release tablets. His contribution is critical as he leads the investigation into improving anxiety treatment through innovative drug delivery methods, reflecting a dedicated effort towards pharmaceutical advancements.

5) Table:
A tabular representation of data, often summarizing experimental results. In this document, tables are employed to present various experimental parameters systematically, such as pre-compression and post-compression evaluations, showcasing the effects of different formulations on drug release and physical properties of the tablets.

6) Study (Studying):
A systematic investigation aimed at discovering facts or principles. The research conducted evaluates the formulation of gastro retentive controlled release tablets for Chlordiazepoxide, seeking to improve therapeutic efficacy and patient adherence while minimizing side effects, ultimately contributing to advancements in pharmacotherapeutic methods.

7) Accumulation (Accumulating, Accumulate):
The gathering of substances over time, which can lead to increased effects or toxicities. In the context of Chlordiazepoxide, accumulation of the drug and its metabolites can cause side effects; thus, controlled release formulations aim to minimize this issue by maintaining stable drug levels in the blood.

8) Anxiety:
A mental health condition characterized by excessive worry and fear about future events. The study focuses on Chlordiazepoxide's role as an anxiolytic treatment, aiming to provide prolonged medication effects with fewer side effects, thereby enhancing the quality of life for patients suffering from anxiety disorders.

9) India:
The country where the research took place, showcasing local pharmaceutical advancements. Identifying the geographical context emphasizes the importance of drug development in addressing domestic health issues, specifically targeting prevalent mental health conditions such as anxiety disorders and emphasizing the need for effective treatment options in India.

10) Post:
Referring to the evaluation or action taken after an event. In the context of this study, 'post' parameters evaluate the quality and efficacy of drug formulations after they have been manufactured, ensuring that the resulting tablets meet necessary standards for use and safety.

11) Pur:
Describing inadequate quality or performance. In pharmacology, poor drug delivery can result in varied therapeutic outcomes. The study aims to address these shortcomings by developing formulations that improve drug release profiles, highlighting the need for improved methods in drug formulation to enhance treatment effectiveness.

12) Activity:
Referring to the action of the drug in eliciting a response in the body. Drug activity is pivotal in determining the therapeutic effectiveness of Chlordiazepoxide as an anxiolytic, and is a core focus of the study, aiming to ensure enhanced performance through optimized formulations.

13) Surface:
The outermost boundary of a substance that can interact with surrounding media. In the context of drug release, surface characteristics of tablets significantly affect dissolution and absorption, and the study investigates how tablet surface properties impact the release rates of Chlordiazepoxide in various conditions.

14) Medium:
The environment in which drug release studies are conducted, often a solution that mimics physiological conditions. The choice of medium is crucial, as it influences the drug's dissolution and absorption behavior, providing insights into the efficacy of the gastro retentive controlled release formulations developed in the study.

15) Heap:
A collection of powder or granules, often representative of how active ingredients and excipients are mixed prior to tablet compression. The characteristics of the heap, including flow properties, directly influence the manufacturing process and quality of the final pharmaceutical product in this research.

16) Mental disorder:
A term used to describe various psychological conditions characterized by disruptions in mood and behavior. This study focuses on the formulation of Chlordiazepoxide tablets aimed at treating such disorders, illustrating the potential of improved drug delivery systems to enhance patient care and efficacy of treatment.

17) Measurement:
The process of quantifying physical or chemical properties. In this study, measurement techniques assess the physical attributes of the drug tablets, like hardness and dissolution rates, ensuring that the formulations developed meet the necessary standards for quality and performance in therapeutic applications.

18) Discussion:
An analysis and interpretation of results obtained during research. The discussion section of the study evaluates findings related to the formulation of Chlordiazepoxide tablets, exploring the implications of the data in the context of therapeutic efficacy, stability, and patient outcomes in anxiety treatment.

19) Depression:
A mood disorder characterized by persistent sadness and loss of interest. While the study focuses on anxiety, understanding related conditions like depression highlights the broader context of mental health treatment, emphasizing the need for effective anxiolytic therapies that can also address overlapping mental health issues.

20) Relative:
Comparative terms used to express relationships. In this context, relative parameters assess the performance of different formulations of Chlordiazepoxide tablets against one another, focusing on how variations in composition affect dissolution rates and efficacy, ultimately leading to optimized therapeutic outcomes.

21) Channel:
A specific pathway for substance movement, particularly concerning drug absorption in pharmaceuticals. In this study, the focus on drug channels pertains to the pharmacodynamics of Chlordiazepoxide, understanding how the drug interacts with GABA receptors in the brain to exert its therapeutic anxiolytic effects.

22) Krishna (Krsna):
Dr. K. S. Murali Krishna is acknowledged in the study for his support. Recognition of authorities in pharmaceutical development underscores the collaborative nature of research and the importance of mentorship in advancing the understanding and formulation of effective drug therapies.

23) Nature:
The inherent characteristics or properties of substances. The nature of the polymers used in the formulation (HPMC K4M and Xanthum gum) is pivotal, as their swelling capacity and release properties directly impact the effectiveness of the gastro retentive controlled release tablets for Chlordiazepoxide.

24) Glass:
A transparent solid often used in laboratory equipment like beakers and flasks. Glass containers referenced in the study are used for dissolution testing, crucial for evaluating how the tablet formulations behave in simulated physiological conditions, essential for determining efficacy and release profiles.

25) Blood:
The fluid that transports oxygen and nutrients throughout the body. Chlordiazepoxide's release and absorption into the bloodstream are critical factors in evaluating its therapeutic effectiveness, as maintaining stable plasma concentrations can reduce side effects and improve patient adherence to anxiety treatments.

26) Worry (Worried, Worrying):
An emotional response characterized by feelings of unease and apprehension about potential future events. Worry is a key symptom of anxiety disorders, and this study aims to alleviate excessive worry through effective treatment with Chlordiazepoxide, emphasizing the role of proper drug formulation and delivery systems.

27) Fear:
An emotional response to perceived threats or danger, prevalent in anxiety disorders. Fear reflects the psychological aspect of anxiety that Chlordiazepoxide targets. Understanding the roots of these emotions emphasizes the need for effective anxiolytics and calls for innovative formulations to mitigate these feelings sustainably.

28) Life:
A term encompassing the existence and experiences of individuals. Improving life quality is a primary goal of pharmaceutical interventions. This study endeavors to enhance the lives of individuals suffering from anxiety by optimizing therapies like Chlordiazepoxide through advanced, controlled drug release formulations.